Skip to main content
| News

DayOne healthtech accelerator launches new offering

31.03.2022

DayOne shares the launch of DayOne Accelerator 2.0, marking a transition to three verticals that will enable the growth of global healthcare and medtech startups at various stages of development.

Three new verticals will support a wider community of innovators from concept to mid-stage ventures. Each selected team will receive equity-free funding up to CHF 100,000 in addition to 1-2-1 coaching, tailored mentoring and training, workspace, industry-wide visibility and access to DayOne’s 2,000+ network of key digital health experts.

Learn more [DayOne Accelerator – Day One]

The three verticals include:

Digital Health Nation

An NTN Innovation Booster powered by Innosuisse for researchers and entrepreneurs with a radical idea to transform digital health and patient care in Switzerland. Stages include identifying customer needs and feasibility, determining profitability and product creation to turn hypotheses into a minimum viable product with up to CHF 20,000 non-dilutive funding.

DayOne Tech

A 12 month program for medtech startups, offering the funding, space (Canton of Jura), and guidance needed to turn prototypes into medical devices ready for market launch. Includes up to 150 hours of coaching and up to CHF 100,000 non-dilutive funding to support ambitious milestones and long term business success.

DayOne Health 4.0

A 12 week intense program for early (pre-seed) to mid-stage (pre-series B) digital health ventures from all over the world looking to scale into a successful pharmaceutical business. Entrepreneurs will gain access to a personal coach and advisors, engage with our Pharma partners along the program to build your business model at their interface and showcase your collaboration proposal at a private Demo Day. You will also receive up to CHF 15,000 non-dilutive funding to work on priority areas and get your venture closer to a potential collaboration with our partners.

Learn more about DayOne Health 4.0.

Located in Europe’s healthtech capital, applicants across all verticals will benefit from unlimited access to world-leading research institutes as well as an extensive pool of specialists and collaborators with which to grow their company.

Interested in applying?

Registration for DayOne Accelerator 2.0 is now open to digital health and medtech startups around the world. Express your interest and join one of Europe’s largest healthcare ecosystems today.

I’m interested! Apply – Day One

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest, Sustainability

KUORI developing biodegradable plastics

The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Cell and gene therapies gain momentum in Basel

Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...

Read More
BLKB expanding support for startups
Basel Area Business & Innovation, Innovation, Invest

BLKB expanding support for startups

BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...

Read More
Combatting the rise of antimicrobial resistance
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Combatting the rise of antimicrobial resistance

Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

AMR Action Fund invests in new antibiotics developed by BioVersys

The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Investors give Resistell 8.5 million Swiss francs

Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...

Read More
1 2 3 60

Do you have a question? We'd like to hear from you.